@stemcellsciencenews.comNew in @commsmed.nature.com: study findings (@ucl.ac.uk) highlight limitations in the representativeness of widely used #ProstateCancer cell lines and emphasize the importance of selecting models according to their clinical and molecular relevance.
@genesndiseases.bsky.socialCould #ferroptosis overcome treatment resistance in #ProstateCancer?
This review highlights key regulatory pathways, biomarkers and combination strategies with anti-androgen therapy, chemotherapy and #immunotherapy.
#OpenAccess in #GenesAndDiseases: doi.org/10.1016/j.ge...
@uicancercenter.bsky.socialCancer Center member Natalie Reizine, MD, is featured in a @cureswithinreach.bsky.social Researcher Spotlight for her clinical trial exploring glycyrrhizin as a potential treatment for #prostatecancer, inspired by patient questions and lab research.
Read more here: https://bit.ly/4hH1A88
@evertonthesitcom.bsky.socialHad a shite few days, lots of fatigue and annoying pain.Most of the time I feel like im sagging off work,the last days have been tough, but Im just starting to get back to myself, hence I've been quiet on here!
Get checked lads, this shits no fun at times!
#prostatecancer
@jamanetworkopen.comIn metastatic androgen pathway modulator-resistant #ProstateCancer, outcomes with Lu-177 prostate-specific membrane antigen were broadly consistent across treatment lines and taxane sequencing groups.
@vcclibrary.bsky.socialArtificial Intelligence for #ProstateCancer Detection and Screening on MRI in Global Populations: The SCARLET-1 Study. pubs.rsna.org/doi/10.1148/...
@vcclibrary.bsky.socialPhase I/II Study of Bavdegalutamide, a Proteolysis-Targeting Chimera Androgen Receptor Degrader, in Metastatic Castration-Resistant #ProstateCancer. ascopubs.org/doi/10.1200/...
@vcclibrary.bsky.socialDose-Escalated Focal Salvage High-Dose-Rate Brachytherapy and Genomic Classifier Risk Stratification in Radiorecurrent #ProstateCancer: The F-SHARP Phase I/II Clinical Trial. ascopubs.org/doi/10.1200/...
@academaxjournals.bsky.socialDoes surgical choice influence long-term prostate cancer outcomes?
A meta-analysis found lower incontinence rates with robot-assisted radical prostatectomy than with open or laparoscopic surgery, and lower mortality than with open surgery.
doi.org/10.1016/j.le...
@dximaging-mjh.bsky.socialWhat a Large Prostate #MRI Study Reveals About #AI and Unassisted Radiologist Assessment
www.diagnosticimaging.com/view/prostat...
#radiology #RadRes #ProstateCancer
@brianwernham.bsky.socialChatGPT is guiding me how to check GA68 PSMA uptake in my Liver as a reference for PSMA-RADS scoring my PET scan
Step by step, using 3D slicer
It is checking I don't make any mistakes and helping me just as a university tutor would
I am my own radiologist...
@renalurologynews.bsky.socialThe Decipher 22-gene genomic classifier identifies men with intermediate-risk #ProstateCancer who are more likely to benefit from the addition of short-term androgen deprivation therapy to dose-escalated RT.
See more🔽
https://bit.ly/4edlMw5
@ancan501c3.bsky.socialOne of many #prostatecancer virtual support groups
Low/Intermediate Risk #ActiveSurveillance Prostate Cancer meets weekly on the 1st-4th Wednesday of the month. Free & drop-in; Join directly here:
https://www.gotomeet.me/AnswerCancer
@dhsc-answers.bsky.socialA question on #ProstateCancer #Screening tabled by Jim Dickson on 09-10-2026 has been answered by Dame Diana Johnson. https://questions-statements.parliament.uk/written-questions/detail/2026-10-09/33111
@dximaging-mjh.bsky.socialComparative #PSMA PET Study Offers Insights for Men with Recurrent PCa and Low PSA Values
www.diagnosticimaging.com/view/molecul...
#radiology #RadRes #NuclearMedicine #ProstateCancer
@doublewhammied.bsky.social“The way we name things provides an initial perspective when we refer 2 a med'l condition; it creates a preconceived notion abt the illness in ppl, which is why it's rec'd that we exercise great caution w/our language.”
💯! Castration-resistant #prostatecancer is an awful name! Others? #CanSky
@medliveofficial.bsky.socialClosing the mCSPC treatment intensification gap starts with informed decisions. Join this live program exploring doublet and triplet strategies, ARASEC findings, and real-world care.
▶️ Register: vist.ly/5n863
@wcmenglanderipm.bsky.socialCongratulations to our Clinical Director Dr. Cora N. Sternberg (@cnsternberg) on her new @JCO_ASCO paper, "Phase I/II Study of #Bavdegalutamide, a #PROTAC Androgen Receptor Degrader, in Metastatic Castration-Resistant #ProstateCancer."
@healthcare-europe.bsky.socialA combined approach of two #biopsy techniques involving PSMA #PET/CT may help identify clinically significant #prostatecancer that would otherwise be difficult to detect, according to new research published by @snm-mi.bsky.social.
@spartanbrotherhq.bsky.socialProstate cancer outcomes are improving, but inequalities remain.
Black men face twice the risk. Awareness, early conversations and equal access to care matter.
Every man deserves support.
🛡️ No Man Fights Alone.
